Pneumococcal infection and its vaccine control
DOI:
https://doi.org/10.31073/onehealthjournal2026-I-01Keywords:
pneumococcal infection, immunity, prevention, vaccination, effectivenessAbstract
Pneumococcal infection is caused by more than 100 serotypes of S. pneumoniae (Spn), as well as non-encapsulated pneumococci. The greatest danger is posed by invasive pneumococcal infections (IPI), when the pathogen is found in locations that should be sterile. IPI most often includes meningitis and septic conditions. Spn caused between 929,000 and 1.4 million deaths worldwide only in 2019. The widespread use of pneumococcal conjugate vaccines (PCVs) for children in vaccination programs has significantly influenced the epidemiological process of this infection, gradually leading to a decrease in the effectiveness of PCVs and accompanied by an increase in the number of Spn serotypes in PCVs due to previously non-vaccinal serotypes (NVST), which became invasive and relevant in the process of expanding the scope of vaccination. The aim of the study was to analyze changes in the invasiveness of Spn from different serotypes against the background of vaccination, the evolution of PCVs, and the prospects for vaccine control of pneumococcal infection. The paper provides an analysis of literature data on the high efficacy of PCVs against IPI caused by vaccine serotypes (VST) Spn, the gradual serotype change of invasive Spn and their acquisition of epidemic relevance, multidrug resistance; risks associated with nonencapsulated Spn; dynamics of increasing valency of PCV serotypes (from PCV7 to PCV21, development of PCV24, PCV25, and PCV31) and their further impact on the epidemic process in different countries and regions of the world. The impact of vaccination on the composition of the upper respiratory tract microbiome was discussed, as well as differences in IPI levels in different territories and their causes. It was demonstrated that vaccination against pneumococcal infection does not provide a warranty of protection even against fatal cases due to the acquisition of highly invasive properties by NVST. The use of PCVs does not adequately affect the intensity of circulation of some VSTs (types 3 and 19A). The dynamics of IPI levels (2010–2022) and changes in the dominant Spn serotypes were analyzed using the example of EU/EEA countries. In 17 (63%) of 27 countries, there was a tendency for IPI to increase against the backdrop of long-term vaccination; in 3 (11%), there was a stable trend; in 7 (26%), there was a decline in morbidity. However, even with a downward trend, the IPI levels in some countries exceeded those in some countries where an upward trend was observed. The total IPI cases for these countries did not actually decrease and ranged from 5.7 to 6.4 per 100,000 population, with a moderate upward trend. The results of our analysis show that the widespread use of PCVs, even with an increase in their valence, will require constant replacement of current serotypes, without actually significantly affecting IPI levels. This does not allow us to talk about vaccine control of IPI either now or in the future. We see the only optimal solution for curbing the accelerated artificial evolution of Spn, stabilizing the epidemic process, and optimizing the use of PCVs as directing the vaccination strategy toward medical and epidemic risk groups.References
Dion C.F., Ashurst J.V. (2025). Streptococcus pneumoniae. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470537/
Government of Singapore, Communicable Diseases Agency. (2025, March 26). Invasive pneumococcal disease (Streptococcus pneumoniae). https://www.cda.gov.sg/professionals/diseases/invasive-pneumococcal-disease
Chen C.-H., Chen C.-L., Su L.-H., Chen C.-J., Tsai M.-H., Chiu C.-H. (2025). The microbiological characteristics and diagnosis of Streptococcus pneumoniae infection in the conjugate vaccine era. Human Vaccines & Immunotherapeutics, 21(1), Article 2497611. https://doi.org/10.1080/21645515.2025.2497611
Mrabt F., Guedes, S. (2025). Systematic review on serotypes distribution of pneumococcal pneumonia in adults and the elderly. BMC Public Health, 25, 1194. https://doi.org/10.1186/s12889-025-22164-x
Tothpal A., Desobry K., Joshi S., et al. (2019). Variation of growth characteristics of pneumococcus with environmental conditions. BMC Microbiology, 19, 304. https://doi.org/10.1186/s12866-019-1671-8
Centers for Disease Control and Prevention. (2024, February 6). Clinical overview of pneumococcal disease. https://www.cdc.gov/pneumococcal/hcp/clinical-overview/index.html
Henriques-Normark B., Tuomanen, E.I. (2013). The pneumococcus: Epidemiology, microbiology, and pathogenesis. Cold Spring Harbor Perspectives in Medicine, 3(7), a010215. https://doi.org/10.1101/cshperspect.a010215
Luck J.N., Tettelin H., Orihuela C.J. (2020). Sugar-coated killer: Serotype 3 pneumococcal disease. Frontiers in Cellular and Infection Microbiology, 10, 613287. https://doi.org/10.3389/fcimb.2020.613287
Yue J., Chen L., Yao T., Du P., Gu C., Wei H., Han K., Rong C., Wang C., Zhang Q., Chen C., Liu J., Hua M. (2025). A global epidemic serotype 14 Streptococcus pneumoniae switching to nonvaccine types. Microbiology Spectrum, 13(5), e03151-24. https://doi.org/10.1128/spectrum.03151-24
Croucher N.J., Kagedan L., Thompson C.M., Parkhill J., Bentley S.D., Finkelstein J.A., Lipsitch M., Hanage W.P. (2015). Selective and genetic constraints on pneumococcal serotype switching. PLoS Genetics, 11(3), e1005095. https://doi.org/10.1371/journal.pgen.1005095
Centers for Disease Control and Prevention. (2013). Antibiotic resistance threats in the United States, 2013. U.S. Department of Health and Human Services. https://stacks.cdc.gov/view/cdc/20705
Solomon S.L., Oliver K.B. (2014). Antibiotic resistance threats in the United States: Stepping back from the brink. American Family Physician, 89(12), 938–941.
European Centre for Disease Prevention and Control, European Medicines Agency. (2009). The bacterial challenge: Time to react. Joint technical report. https://doi.org/10.2900/2518
Cilloniz C., Garcia-Vidal C., Ceccato A., Torres A. (2018). Antimicrobial resistance among Streptococcus pneumoniae. In Antimicrobial Resistance in the 21st Century (pp. 13–38). Springer. https://doi.org/10.1007/978-3-319-78538-7_2
Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
Jonas O.B., Irwin A., Berthe F.C.J., Le Gal F.G., Marquez P.V. (2017). Drug-resistant infections: A threat to our economic future (Vol. 1: Executive summary). World Bank Group.
Goldmann D., Rajan S., Udayakumar K. (2024). Preventing and controlling global antimicrobial resistance—Implementing a whole-system approach. New England Journal of Medicine, 391(8), 681–685. https://doi.org/10.1056/NEJMp2401360
Li L., Ma J., Yu Z., Li M., Zhang W., Sun H. (2023). Epidemiological characteristics and antibiotic resistance mechanisms of Streptococcus pneumoniae: An updated review. Microbiological Research, 266, 127221. https://doi.org/10.1016/j.micres.2022.127221
Centers for Disease Control and Prevention. (2024). Antibiotic-resistant Streptococcus pneumoniae. https://www.cdc.gov/pneumococcal/php/drug-resistance/index.html
Peters K., Schweizer I., Hakenbeck R., Denapaite D. (2021). New insights into beta-lactam resistance of Streptococcus pneumoniae: Serine protease HtrA degrades altered penicillin-binding protein 2x. Microorganisms, 9(8), 1685. https://doi.org/10.3390/microorganisms9081685
Ambrose K.D., Nisbet R., Stephens D.S. (2005). Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible. Antimicrobial Agents and Chemotherapy, 49(10), 4203–4209. https://doi.org/10.1128/AAC.49.10.4203-4209.2005
Schroeder M.R., Stephens D.S. (2016). Macrolide resistance in Streptococcus pneumoniae. Frontiers in Cellular and Infection Microbiology, 6, 98. https://doi.org/10.3389/fcimb.2016.00098
Schroeder M.R., Lohsen S., Chancey S.T., Stephens D.S. (2019). High-level macrolide resistance due to the Mega element [mef(E)/mel] in Streptococcus pneumoniae. Frontiers in Microbiology, 10, 868. https://doi.org/10.3389/fmicb.2019.00868
Chancey S.T., Bai X., Kumar N., Drabek E.F., Daugherty S.C., Colon T., Ott S., Sengamalay N., Sadzewicz L., Tallon L.J., Fraser C.M., Tettelin H., Stephens D.S. (2015). Transcriptional attenuation controls macrolide inducible efflux and resistance in Streptococcus pneumoniae and in other Gram-positive bacteria containing mef/mel (msr(D)) elements. PLoS One, 10(2), e0116254. https://doi.org/10.1371/journal.pone.0116254
Zeller V., Janoir C., Kitzis M.D., Gutmann L., Moreau N.J. (1997). Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 41(9), 1973–1978. https://doi.org/10.1128/AAC.41.9.1973
Keness Y., Bisharat N. (2016). Draft genome sequences of Streptococcus pneumoniae with high-level resistance to respiratory fluoroquinolones. Genome Announcements, 4(2), e00181-16. https://doi.org/10.1128/genomeA.00181-16
Manyahi J., Moyo S., Aboud S., Langeland N., Blomberg B. (2020). High rate of antimicrobial resistance and multiple mutations in the dihydrofolate reductase gene among Streptococcus pneumoniae isolated from HIV-infected adults in a community setting in Tanzania. Journal of Global Antimicrobial Resistance, 22, 749–753. https://doi.org/10.1016/j.jgar.2020.06.026
Manyahi J., Moyo S.J., Langeland N., Blomberg B. (2023). Genetic determinants of macrolide and tetracycline resistance in penicillin non-susceptible Streptococcus pneumoniae isolates from people living with HIV in Dar es Salaam, Tanzania. Annals of Clinical Microbiology and Antimicrobials, 22(1), 16. https://doi.org/10.1186/s12941-023-00565-3
Lusta M., Voronkova O., Shevchenko T., Chornyi V., Breus A., Yesaulenko I., Maistrenko Y., Shyrokykh Y., Falko O. (2024). Colonization and antimicrobial resistance of Streptococcus pneumoniae among pediatric patients. Regulatory Mechanisms in Biosystems, 15(4), 926–931. https://doi.org/10.15421/0224135
Musher D.M., Anderson R., Feldman C. (2022). The remarkable history of pneumococcal vaccination: An ongoing challenge. Pneumonia, 14(1), 5. https://doi.org/10.1186/s41479-022-00097-y
McGuinness D., Kaufhold R.M., McHugh P.M., Winters M.A., Smith W.J., Giovarelli C., He J., Zhang Y., Musey L., Skinner J.M. (2021). Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine, 39(30), 4231–4237. https://doi.org/10.1016/j.vaccine.2021.04.067
Chichili G.R., Smulders R., Santos V., Cywin B., Kovanda L., Van Sant C., Malinoski F., Sebastian S., Siber G., Malley R. (2022). Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Vaccine, 40(31), 4190–4198. https://doi.org/10.1016/j.vaccine.2022.05.079
Wassil J., Sisti M., Fairman J., Davis M., Fierro C., Bennett S., Johnson D., Migone T.S., Nguyen K., Sauer P., Currie M., Iki S., Simon J.K. (2024). Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: A phase 1/2, double-masked, dose-finding, active-controlled, randomized clinical trial. Lancet Infectious Diseases, 24(3), 308–318. https://doi.org/10.1016/S1473-3099(23)00572-8
ClinicalTrials.gov. (2025). Phase II clinical trial of 24-valent pneumococcal polysaccharide conjugate vaccine (NCT07035054). https://clinicaltrials.gov/study/NCT07035054
Smith K.J., Wateska A.R., Nowalk M.P., Lin C.J., Harrison L.H., Schaffner W., Zimmerman R.K. (2025). Cost-effectiveness and public health impact of 24-valent pneumococcal conjugate vaccine compared with the recommended pneumococcal vaccines in older adults. American Journal of Preventive Medicine, 68(3), 518–526. https://doi.org/10.1016/j.amepre.2024.11.014
Centers for Disease Control and Prevention. (2024). About pneumococcal vaccines. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/about-vaccine.html
Park I.H., Moore M.R., Treanor J.J., Pelton S.I., Pilishvili T., Beall B., Shelly M.A., Mahon B.E. (2008). Differential effects of pneumococcal vaccines against serotypes 6A and 6C. Journal of Infectious Diseases, 198(12), 1818–1822. https://doi.org/10.1086/593339
van der Linden M., Falkenhorst G., Perniciaro S., Fitzner C., Imohl M. (2016). Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One, 11(8), e0161257. https://doi.org/10.1371/journal.pone.0161257
Gjini E. (2017). Geographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7. Scientific Reports, 7, 3049. https://doi.org/10.1038/s41598-017-02955-y
Biesbroek G., Wang X., Keijser B.J.F., Eijkemans R.M.J.C., Trzcinski K., Rots N.Y., Veenhoven R.H., Sanders E.A.M., Bogaert D. (2014). Seven-valent pneumococcal conjugate vaccine and nasopharyngeal microbiota in healthy children. Emerging Infectious Diseases, 20(2), 201–210. https://doi.org/10.3201/eid2002.131220
Bennett J.C., Deloria Knoll M., Kagucia E.W., Garcia Quesada M., Zeger S.L., Hetrich M.K., Yang Y., Herbert C., Ogyu A., Cohen A.L., Yildirim I., Winje B.A., von Gottberg A., Viriot D., van der Linden M., Valentiner-Branth P., Suga S., Steens A., Skoczynska A., Sinkovec Zorko N., Scott J.A., Savulescu C., Savrasova L., Sanz J.C., Russell F., Ricketson L.J., Puentes R., Nuorti J.P., Mereckiene J., McMahon K., McGeer A., Madarova L., Mackenzie G.A., MacDonald L., Lepp T., Ladhani S.N., Kristinsson K.G., Kozakova J., Klein N.P., Jayasinghe S., Ho P.L., Hilty M., Heyderman R.S., Hasanuzzaman M., Hammitt L.L., Guevara M., Grgic-Vitek M., Gierke R., Georgakopoulou T., Galloway Y., Diawara I., Desmet S., De Wals P., Dagan R., Colzani E., Cohen C., Ciruela P., Chuluunbat U., Chan G., Camilli R., Bruce M.G., Brandileone M.C., Bigogo G., Ampofo K., O'Brien K.L., Feikin D.R., Hayford K.; PSERENADE Team. (2025). Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): A global surveillance analysis. Lancet Infectious Diseases, 25(4), 457–470. https://doi.org/10.1016/S1473-3099(24)00665-0
Garcia Quesada M., Peterson M.E., Bennett J.C., Hayford K., Zeger S.L., Yang Y., Hetrich M.K., Feikin D.R., Cohen A.L., von Gottberg A., van der Linden M., van Sorge N.M., de Oliveira L.H., de Miguel S., Yildirim I., Vestrheim D.F., Verani J.R., Varon E., Valentiner-Branth P., Tzanakaki G., Sinkovec Zorko N., Setchanova L.P., Serhan F., Scott K.J., Scott J.A., Savulescu C., Savrasova L., Reyburn R., Oishi K., Nuorti J.P., Napoli D., Mwenda J.M., Munoz-Almagro C., Morfeldt E., McMahon K., McGeer A., Madarova L., Mackenzie G.A., Leon M.E., Ladhani S.N., Kristinsson K.G., Kozakova J., Kleynhans J., Klein N.P., Kellner J.D., Jayasinghe S., Ho P.L., Hilty M., Harker-Jones M.A., Hammitt L.L., Gilkison C., Gierke R., French N., Diawara I., Desmet S., De Wals P., Dalby T., Dagan R., Corcoran M., Colzani E., Chanto Chacon G., Castilla J., Camilli R., Ang M., Ampofo K., Almeida S.C.G., Alarcon P., O'Brien K.L., Deloria Knoll M.; PSERENADE Team. (2025). Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): A global surveillance analysis. Lancet Infectious Diseases, 25(4), 445–456. https://doi.org/10.1016/S1473-3099(24)00588-7
Redin A., Ciruela P., de Sevilla M.F., Gomez-Bertomeu F., Gonzalez-Peris S., Benitez M.A., Trujillo G., Diaz A., Jou E., Izquierdo C., Perez-Moreno M.O., Moraga-Llop F., Olsina M., Vinado B., Sanfeliu E., Garcia A., Gonzalez-di Lauro S., Garcia-Garcia J.J., Dominguez A., Sa-Leao R., Munoz-Almagro C.; Catalan Study Group of Invasive Pneumococcal Disease. (2021). Serotypes and clonal composition of Streptococcus pneumoniae isolates causing invasive pneumococcal disease in Catalonia before 2013–2015 and after 2017–2019 systematic introduction of PCV13. Microbiology Spectrum, 9(3), e0115021. https://doi.org/10.1128/Spectrum.01150-21
Atici S., Guneser D., Kepenekli E., et al. (2025). Serotypes distribution and antibiotic susceptibility of Streptococcus pneumoniae strains: Five-year surveillance results of post-PCV-13. BMC Pediatrics, 25, 244. https://doi.org/10.1186/s12887-025-05593-w
Muller A., Kleynhans J., de Gouveia L., Meiring S., Cohen C., Hathaway L.J., von Gottberg A.; GERMS-SA. (2022). Streptococcus pneumoniae serotypes associated with death, South Africa, 2012–2018. Emerging Infectious Diseases, 28(1), 166–179. https://doi.org/10.3201/eid2801.210956
Yang Y., Knoll M.D., Herbert C., Bennett J.C., Feikin D.R., Garcia Quesada M., Hetrich M.K., Zeger S.L., Kagucia E.W., Xiao M., Cohen A.L., van der Linden M., du Plessis M., Yildirim I., Winje B.A., Varon E., Valenzuela M.T., Valentiner-Branth P., Steens A., Scott J.A., Savrasova L., Sanz J.C., Khan A.S., Oishi K., Nzoyikorera N., Nuorti J.P., Mereckiene J., McMahon K., McGeer A., Mackenzie G.A., MacDonald L., Ladhani S.N., Kristinsson K.G., Kleynhans J., Kellner J.D., Jayasinghe S., Ho P.L., Hilty M., Hammitt L.L., Guevara M., Gilkison C., Gierke R., Desmet S., De Wals P., Dagan R., Colzani E., Ciruela P., Chuluunbat U., Chan G., Camilli R., Bruce M.G., Brandileone M.C., Ampofo K., O'Brien K.L., Hayford K.; PSERENADE Team. (2025). Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project. Journal of Infection, 90(3), 106426. https://doi.org/10.1016/j.jinf.2025.106426
Phung N.T.N., Tran M.N., Tran T.T., Dang Q.D., Phan H.T. (2025). Fatal purpura fulminans caused by Streptococcus pneumoniae serotype 15AF in a 15-month-old infant. Pediatric Infectious Disease Journal. Advance online publication. https://doi.org/10.1097/INF.0000000000004923
Kawaguchiya M., Urushibara N., Aung M.S., Ito M., Takahashi A., Habadera S., Kobayashi N. (2020). High prevalence of antimicrobial resistance in non-vaccine serotypes of noninvasive/colonization isolates of Streptococcus pneumoniae: A cross-sectional study eight years after the licensure of conjugate vaccine in Japan. Journal of Infection and Public Health, 13(8), 1094–1100. https://doi.org/10.1016/j.jiph.2020.04.012
Contou D., Coudroy R., Colin G., Tadie J.M., Cour M., Sonneville R., Mekontso Dessap A., de Prost N.; HOPEFUL Study Group. (2020). Pneumococcal purpura fulminans in asplenic or hyposplenic patients: A French multicenter exposed-unexposed retrospective cohort study. Critical Care, 24(1), 68. https://doi.org/10.1186/s13054-020-2769-y
Hale A.J., LaSalvia M., Kirby J.E., Kimball A., Baden R. (2016). Fatal purpura fulminans and Waterhouse-Friderichsen syndrome from fulminant Streptococcus pneumoniae sepsis in an asplenic young adult. IDCases, 6, 1–4. https://doi.org/10.1016/j.idcr.2016.08.004
Luck J.N., Tettelin H., Orihuela C.J. (2020). Sugar-coated killer: Serotype 3 pneumococcal disease. Frontiers in Cellular and Infection Microbiology, 10, 613287. https://doi.org/10.3389/fcimb.2020.613287
Choi E.H., Zhang F., Lu Y.J., Malley R. (2015). Capsular polysaccharide release by serotype 3 pneumococcal strains reduces the protective effect of anti–type 3 CPS antibodies. Clinical and Vaccine Immunology, 23(2), 162–167. https://doi.org/10.1128/CVI.00591-15
Babb R., Doyle C.R., Pirofski L.A. (2021). Isolation and characterization of human monoclonal antibodies to pneumococcal capsular polysaccharide 3. Microbiology Spectrum, 9(3), e0144621. https://doi.org/10.1128/Spectrum.01446-21
Calvo-Silveria S., Gonzalez-Diaz A., Grau I., Marimon J.M., Cercenado E., Quesada M.D., Casabella A., Larrosa N., Yuste J., Berbel D., Alonso M., Tubau F., Belman S., Cadenas-Jimenez I., Martin-Galiano A.J., Dominguez M.A., Marti S., Linares J., Pallares R., Camara J., Ardanuy C. (2024). Evolution of invasive pneumococcal disease by serotype 3 in adults: A Spanish three-decade retrospective study. The Lancet Regional Health – Europe, 41, 100913. https://doi.org/10.1016/j.lanepe.2024.100913
Cleary D.W., Lo S.W., Kumar N., Bentley S.D., Faust S.N., Clarke S.C. (2023). Comparative genomic epidemiology of serotype 3 invasive pneumococcal disease and carriage isolates from Southampton, UK between 2005 and 2017. Microbial Genomics, 9(3), mgen000945. https://doi.org/10.1099/mgen.0.000945
Cella E., Sutcliffe C.G., Grant L.R., Tso C., Weatherholtz R.C., Littlepage S., Becenti L., Jubair M., Simons B.C., Harker-Jones M., Reid R., Yazzie D., Santosham M., O'Brien K.L., Hammitt L.L., Azarian T. (2024). Streptococcus pneumoniae serotype 3 population structure in the era of conjugate vaccines, 2001–2018. Microbial Genomics, 10(3), 001196. https://doi.org/10.1099/mgen.0.001196
Tothpal A., Laub K., Kardos S., Tirczka T., Kocsis A., van der Linden M., Dobay O. (2016). Epidemiological analysis of pneumococcal serotype 19A in healthy children following PCV7 vaccination. Epidemiology and Infection, 144(7), 1563–1573. https://doi.org/10.1017/S0950268815002757
Corcoran M., Mereckiene J., Cotter S., Murchan S., Lo S.W., McGee L., Breiman R.F., Cunney R., Humphreys H., Bentley S.D., Gladstone R.A. (2021). Using genomics to examine the persistence of Streptococcus pneumoniae serotype 19A in Ireland and the emergence of a sub-clade associated with vaccine failures. Vaccine, 39(35), 5064–5073. https://doi.org/10.1016/j.vaccine.2021.06.017
Ruiz Garcia Y., Nieto Guevara J., Izurieta P., Vojtek I., Ortega-Barria E., Guzman-Holst A. (2021). Circulating clonal complexes and sequence types of Streptococcus pneumoniae serotype 19A worldwide: The importance of multidrug resistance—A systematic literature review. Expert Review of Vaccines, 20(1), 45–57. https://doi.org/10.1080/14760584.2021.1873136
Yue J., Chen L., Yao T., Du P., Gu C., Wei H., Han K., Rong C., Wang C., Zhang Q., Chen C., Liu J., Hua M. (2025). A global epidemic serotype 14 Streptococcus pneumoniae switching to nonvaccine types. Microbiology Spectrum, 13(5), e0315124. https://doi.org/10.1128/spectrum.03151-24
Darkwah S., Somda N.S., Mahazu S., Donkor E.S. (2025). Pneumococcal serotypes and their association with death risk in invasive pneumococcal disease: A systematic review and meta-analysis. Frontiers in Medicine, 12, 1566502. https://doi.org/10.3389/fmed.2025.1566502
Lo S.W., Gladstone R.A., van Tonder A.J., Lees J.A., du Plessis M., Benisty R., Givon-Lavi N., Hawkins P.A., Cornick J.E., Kwambana-Adams B., Law P.Y., Ho P.L., Antonio M., Everett D.B., Dagan R., von Gottberg A., Klugman K.P., McGee L., Breiman R.F., Bentley S.D.; Global Pneumococcal Sequencing Consortium. (2019). Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: An international whole-genome sequencing study. Lancet Infectious Diseases, 19(7), 759–769. https://doi.org/10.1016/S1473-3099(19)30297-X
European Centre for Disease Prevention and Control. (2016). Annual epidemiological report 2016: Invasive pneumococcal disease. ECDC.
European Centre for Disease Prevention and Control. (2025). Annual epidemiological reports (AERs). https://www.ecdc.europa.eu/en/publications-data/monitoring/all-annual-epidemiological-reports
European Centre for Disease Prevention and Control. (2025). Invasive pneumococcal disease: Annual epidemiological report for 2022. ECDC. https://www.ecdc.europa.eu/sites/default/files/documents/PNEU_AER_2022_Report.pdf
Zadorozhna V.I., Vynnyk N.P., Serheieva T.A., Marichev I.L., Brighata S.I., Demchishina I.V. (2024). Analysis of the measles incidence in Ukraine and the population immunity. Ukrainian Journal of Military Medicine, 5(2), 48–60. https://doi.org/10.46847/ujmm.2024.2(5)-048
Zadorozhna V.I., Vynnyk N.P., Serheieva T.A., Podavalenko A.P. (2025). Characteristics of the epidemic process of pertussis in Ukraine against the COVID-19 pandemic and martial law. Modern Pediatrics. Ukraine, 3(147), 6–19. https://doi.org/10.15574/SP.2025.3(147).619
Zadorozhna V., Vynnyk N., Serheieva T., Podavalenko A. (2025). Current epidemiology of pertussis and problem issues of vaccine prophylaxis of this infection. Child's Health, 20(6), 470–481. https://doi.org/10.22141/2224-0551.20.6.2025.1906
European Centre for Disease Prevention and Control. (2025). Annual epidemiological reports (AERs). https://www.ecdc.europa.eu/en/publications-data/monitoring/all-annual-epidemiological-reports
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 One Health Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
